ONCT insider filings
Oncternal Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-06-24. Screen ONCT transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for ONCT between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Oncternal Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-06-24 | 4 | THEUER CHARLES — Director | Grant/award (A): 2,200 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | DeSimone Jill — Director | Grant/award (A): 2,200 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | CARTER MICHAEL G — Director | Grant/award (A): 2,200 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | Wills Robert James — Director | Grant/award (A): 2,200 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | LARUE WILLIAM R — Director | Grant/award (A): 2,200 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | MAZANET ROSEMARY — Director | Grant/award (A): 2,200 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | KISNER DANIEL L — Director | Grant/award (A): 2,200 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | HALE DAVID F — Director | Grant/award (A): 3,300 (derivative) @ $0 | EDGAR |
| 2024-04-10 | 4 | Wills Robert James — Director | Purchase (P): 3,086 @ $8.96 | EDGAR |
| 2024-04-01 | 4 | Wills Robert James — Director | Purchase (P): 6,914 @ $8.48 | EDGAR |
| 2024-02-27 | 4 | Wills Robert James — Director | Sale (S): 980 @ $9.04 | EDGAR |
| 2024-02-27 | 4 | HALE DAVID F — Director | Purchase (P): 714 @ $9.04 · Purchase (P): 266 @ $9.04 | EDGAR |
| 2024-02-15 | 4 | Leavitt Chase C. — General Counsel/Secretary | Grant/award (A): 14,200 (derivative) @ $0 | EDGAR |
| 2024-02-15 | 4 | Krishnan Rajesh — CTO/CSO | Grant/award (A): 17,700 (derivative) @ $0 | EDGAR |
| 2024-02-15 | 4 | Yazji Salim — Chief Medical Officer | Grant/award (A): 14,200 (derivative) @ $0 | EDGAR |
| 2024-02-15 | 4 | VINCENT RICHARD G — Chief Financial Officer | Grant/award (A): 14,200 (derivative) @ $0 | EDGAR |
| 2024-02-15 | 4 | BREITMEYER JAMES B — Chief Executive Officer, Director | Grant/award (A): 28,400 (derivative) @ $0 · Grant/award (A): 6,200 (derivative) @ $0 | EDGAR |
| 2024-01-05 | 4 | Krishnan Rajesh — Chief Technical Officer | Tax withholding (F): 11,838 @ $0.50 | EDGAR |
| 2024-01-05 | 4 | Yazji Salim — Chief Medical Officer | Tax withholding (F): 19,742 @ $0.50 | EDGAR |
| 2024-01-05 | 4 | VINCENT RICHARD G — Chief Financial Officer | Tax withholding (F): 8,868 @ $0.50 | EDGAR |
| 2024-01-05 | 4 | Leavitt Chase C. — General Counsel/Secretary | Tax withholding (F): 11,838 @ $0.50 | EDGAR |
| 2024-01-05 | 4 | BREITMEYER JAMES B — Chief Executive Officer, Director | Tax withholding (F): 50,955 @ $0.50 · Tax withholding (F): 4,485 @ $0.50 | EDGAR |
| 2023-10-04 | 4 | Leavitt Chase C. — General Counsel/Secretary | Disposition to issuer (D): 65,000 (derivative) · Disposition to issuer (D): 55,519 (derivative) · Disposition to issuer (D): 28,750 (derivative) · Disposition to issuer (D): 210,000 (derivative) · Grant/award (A): 65,000 (derivative) · Grant/award (A): 55,519 (derivative) · +3 more | EDGAR |
| 2023-10-04 | 4 | Yazji Salim — Chief Medical Officer | Disposition to issuer (D): 354,400 (derivative) · Disposition to issuer (D): 92,075 (derivative) · Disposition to issuer (D): 55,000 (derivative) · Disposition to issuer (D): 210,000 (derivative) · Grant/award (A): 354,400 (derivative) · Grant/award (A): 92,075 (derivative) · +3 more | EDGAR |
| 2023-10-04 | 4 | VINCENT RICHARD G — Chief Financial Officer | Disposition to issuer (D): 75,000 (derivative) · Disposition to issuer (D): 35,120 (derivative) · Disposition to issuer (D): 280,000 (derivative) · Disposition to issuer (D): 109,579 (derivative) · Disposition to issuer (D): 28,750 (derivative) · Disposition to issuer (D): 210,000 (derivative) · +6 more | EDGAR |
| 2023-10-04 | 4 | Krishnan Rajesh — Chief Technical Officer | Disposition to issuer (D): 75,000 (derivative) · Disposition to issuer (D): 40,000 (derivative) · Disposition to issuer (D): 12,470 (derivative) · Disposition to issuer (D): 160,000 (derivative) · Disposition to issuer (D): 177,050 (derivative) · Disposition to issuer (D): 28,750 (derivative) · +8 more | EDGAR |
| 2023-10-04 | 4 | BREITMEYER JAMES B — Chief Executive Officer, Director | Disposition to issuer (D): 100,000 (derivative) · Disposition to issuer (D): 66,890 (derivative) · Disposition to issuer (D): 750,000 (derivative) · Disposition to issuer (D): 637,000 (derivative) · Disposition to issuer (D): 123,750 (derivative) · Disposition to issuer (D): 650,000 (derivative) · +18 more | EDGAR |
| 2023-07-05 | 4 | Leavitt Chase C. — General Counsel/Secretary | Tax withholding (F): 10,305 @ $0.36 | EDGAR |
| 2023-07-05 | 4 | VINCENT RICHARD G — Chief Financial Officer | Tax withholding (F): 7,069 @ $0.36 | EDGAR |
| 2023-07-05 | 4 | Yazji Salim — Chief Medical Officer | Tax withholding (F): 16,299 @ $0.36 | EDGAR |
| 2023-07-05 | 4 | Krishnan Rajesh — Chief Technology Officer | Tax withholding (F): 10,897 @ $0.36 | EDGAR |
| 2023-07-05 | 4 | BREITMEYER JAMES B — Chief Executive Officer, Director | Tax withholding (F): 47,992 @ $0.36 · Tax withholding (F): 4,007 @ $0.36 | EDGAR |
| 2023-06-30 | 4 | THEUER CHARLES — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2023-06-30 | 4 | CARTER MICHAEL G — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2023-06-30 | 4 | Nakanishi Xin — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2023-06-30 | 4 | Wills Robert James — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2023-06-30 | 4 | LARUE WILLIAM R — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2023-06-30 | 4 | MAZANET ROSEMARY — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2023-06-30 | 4 | DeSimone Jill — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2023-06-30 | 4 | KISNER DANIEL L — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2023-06-30 | 4 | HALE DAVID F — Director | Grant/award (A): 37,500 (derivative) @ $0 | EDGAR |
| 2023-06-14 | 4 | Kaufmann Gunnar F. — Chief Scientific Officer | Purchase (P): 25,000 @ $0.35 · Purchase (P): 3,000 @ $0.36 | EDGAR |
| 2023-04-17 | 4 | BREITMEYER JAMES B — Chief Executive Officer, Director | Purchase (P): 100,000 @ $0.29 · Purchase (P): 47,750 @ $0.30 · Purchase (P): 2,250 @ $0.29 | EDGAR |
| 2023-04-14 | 4 | Yazji Salim — Chief Medical Officer | Purchase (P): 10,000 @ $0.28 · Purchase (P): 10,000 @ $0.28 · Purchase (P): 5,000 @ $0.30 | EDGAR |
| 2023-04-14 | 4 | Leavitt Chase C. — General Counsel/Secretary | Purchase (P): 15,000 @ $0.29 · Purchase (P): 10,000 @ $0.29 | EDGAR |
| 2023-04-14 | 4 | VINCENT RICHARD G — Chief Financial Officer | Purchase (P): 30,000 @ $0.30 | EDGAR |
| 2023-02-24 | 4 | BREITMEYER JAMES B — Chief Executive Officer, Director | Grant/award (A): 650,000 (derivative) @ $0 · Grant/award (A): 65,000 (derivative) @ $0 · Grant/award (A): 42,196 (derivative) @ $0 | EDGAR |
| 2023-02-23 | 4 | Kaufmann Gunnar F. — Chief Scientific Officer | Grant/award (A): 210,000 (derivative) @ $0 | EDGAR |
| 2023-02-23 | 4 | VINCENT RICHARD G — Chief Financial Officer | Grant/award (A): 210,000 (derivative) @ $0 | EDGAR |
| 2023-02-23 | 4 | Krishnan Rajesh — Chief Technology Officer | Grant/award (A): 220,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Oncternal Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2024-11-25 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2024-11-14 | 8-K | ? 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2024-09-12 | 8-K | ? 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events | EDGAR |
| 2024-08-08 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-06-21 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2024-05-09 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-03-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-01-23 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-01-05 | 8-K | 2.02 — Results of Operations and Financial Condition 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-11-09 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ONCT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs